Should We Implement Real-Time Telemedical Oversight (ReTMO) with Structured Stroke Protocols and Mobile Stroke Units (MSTUs) for All Suspected Acute Stroke Patients?
Yes, implement mobile stroke units (MSUs) with telemedicine capability wherever available for all suspected acute ischemic stroke patients, as this approach is now a Class I, Level A recommendation that significantly reduces treatment times and improves functional outcomes at 90 days. 1
Evidence-Based Implementation Strategy
Primary Recommendation: Mobile Stroke Units
The 2026 AHA/ASA guidelines provide the strongest evidence for MSU deployment:
- Class I, Level A recommendation: MSUs should be used over conventional EMS for thrombolytic-eligible patients to ensure fastest onset-to-treatment time and improve functional outcomes 1
- Proven mortality and morbidity benefits: The B_PROUD and BEST-MSU randomized trials demonstrated significantly faster thrombolysis and improved 90-day functional outcomes, with benefits strongly related to higher thrombolytic rates within the first golden hour 1
- No safety concerns: All-cause mortality, stroke mimic treatment rates, and symptomatic intracerebral hemorrhage rates were equivalent between MSU and conventional EMS 1
Time Reduction Metrics from High-Quality Evidence
The most recent studies demonstrate dramatic improvements:
- Alarm-to-CT completion: 33 minutes (MSTU) vs 56 minutes (traditional ambulance) 2
- Alarm-to-thrombolysis: 55.5 minutes vs 94 minutes 2
- Door-to-thrombolysis: 31.5 minutes vs 58 minutes 2
- Golden hour treatment: 25-33% of MSU patients receive thrombolysis within 60 minutes of symptom onset compared to <5% with conventional EMS 3
Telemedicine Integration Requirements
MSUs must incorporate neurological expertise through either in-person or telemedicine consultation (Class I, Level B-R) 1:
The 2026 MSU-TELEMED randomized trial directly compared models and found:
- Telemedicine model was superior based on composite hierarchical outcomes of safety, scene-to-treatment-decision time, and resource utilization 4
- Safety events were identical (13% telemedicine vs 12% onboard, risk ratio 0.9) 4
- Median scene-to-treatment-decision time: 19 minutes (telemedicine) vs 13 minutes (onboard) - a clinically acceptable 4-minute difference 4
- Critical advantage: Neurologist time in direct patient care was 100% (telemedicine) vs 33% (onboard), making telemedicine far more resource-efficient 4
Real-Time Telemedical Oversight (ReTMO) for Non-MSU Settings
For hospitals without MSU access, implement structured prehospital stroke protocols with ReTMO (Class I, Level B-R for telestroke in acute settings) 1:
The 2025 cohort study demonstrated:
- Door-to-CT reduction: 10.5 minutes 5
- Door-to-laboratory results reduction: 15.9 minutes 5
- Improved neurological outcomes at discharge: OR = 0.14 (95% CI: 0.02-0.99), meaning 86% reduction in odds of poor neurological outcome 5
Specific Implementation Algorithm
Step 1: Dispatch Phase
- Use telephone stroke assessment tools at 9-1-1 dispatch (Class 2a, Level B-NR) 1
- Prioritize MSU dispatch when available for suspected stroke calls
Step 2: Prehospital Assessment
- MSU teams must include telemedicine or in-person neurologist consultation 1
- Use validated stroke severity scales (Cincinnati Stroke Triage Assessment Tool, RACE, LAMS, FAST-ED) to identify large vessel occlusion 1
- Provide advance notification to receiving hospital (Class I, Level B-NR) 1
Step 3: MSU Equipment Requirements (Class I, Level A) 1
- CT scanner capability for immediate imaging
- Capacity to diagnose and treat with IV thrombolysis
- Telemedicine equipment for remote neurologist consultation
- Point-of-care laboratory testing
Step 4: Destination Decision
- MSUs should identify and triage endovascular thrombectomy-eligible patients to appropriate thrombectomy-capable facilities with prehospital notification (Class 2a, Level B-NR) 1
- For non-MSU transport with suspected large vessel occlusion, consider direct transport to comprehensive stroke center if <15 additional minutes compared to primary stroke center 6
Critical Caveats and Implementation Considerations
Geographic and Resource Constraints:
- Urban settings show greater time reductions (25-41 minutes) compared to rural areas (20-40 minutes), but both demonstrate benefit 3
- The 2026 guidelines acknowledge that cost-effectiveness and optimal deployment strategies require further investigation 1
- Current lack of established reimbursement mechanisms remains a barrier to widespread MSU deployment 6
When MSUs Are Not Available:
- Telestroke systems are effective for IVT decision-making and optimal thrombolytic delivery (Class I, Level B-R) 1
- Telestroke reduces short-term mortality (Class 2a, Level B-NR) 1
- Even telephone consultation with stroke specialist can be beneficial when telemedicine unavailable (Class 2a, Level C-LD) 1
Endovascular Thrombectomy Considerations:
- Recent randomized trials (B_PROUD, BEST-MSU) confirmed MSU benefit for thrombolysis but failed to demonstrate improved clinical outcomes specifically for endovascular thrombectomy 1
- MSUs can be beneficial for identifying and triaging EVT-eligible patients, but evidence is Class 2a, Level B-NR 1
Quality Metrics to Monitor
Hospitals implementing these systems must track (Class I recommendation) 1:
- Door-to-puncture time for thrombectomy
- Successful reperfusion rates
- Long-term patient outcomes
- Scene-to-treatment-decision times for MSUs
- Golden hour thrombolysis rates (target >25%)
Bottom Line for Clinical Practice
The evidence unequivocally supports MSU deployment with telemedicine capability as the optimal prehospital stroke care model. The 2026 guidelines elevated this from a research concept to a Class I recommendation based on multiple randomized trials demonstrating improved functional outcomes and safety. Where MSUs are unavailable, structured ReTMO protocols with telestroke consultation provide significant time savings and outcome improvements over conventional care. The telemedicine model is preferable to onboard neurologist staffing due to superior resource utilization without compromising safety or substantially increasing treatment times.